(1) プロフィール
1987年3月に産業医科大学医学部を卒業し、産業医科大学内科研修医となり、社会保険小倉記念病院研修医、三菱重工下関造船所産業医を経て1990年から1996年まで産業医科大学第一内科で血液内科医員・医長として血液内科診療を行いながら、九州に多い難治性血液疾患である成人T細胞白血病(ATL)についての臨床・基礎研究を行いました。海外留学のチャンスもありましたが、研究テーマのATLが日本で多い疾患で、その患者細胞解析がテーマだったため留学しませんでした。その後、1996年9月から2004年6月まで社会保険小倉記念病院内科で、総合診療内科と併任しつつ血液内科で、非血縁者間骨髄移植や、当時全国的に開発途上だった末梢血幹細胞移植やHLA不一致移植を含めた同種造血幹細胞移植の経験を積みました。2004年7月からは虎の門病院に異動し、血液内科の谷口修一部長に師事し、当時から先駆的治療として開発中だった臍帯血移植に関わり、ミニ移植という手法で高齢者にも適応拡大を図りつつ、臍帯血移植特有と思われる免疫反応の解析をおこなっています。2010年2月からは、虎の門病院分院に新たに血液内科を設立する任を預かり、川崎市をはじめとした神奈川県東部地域の血液中核施設とすべく、当時川崎市では行われなくなっていた造血幹細胞移植を自家・同種とも立ち上げ、全身放射線非照射前処置での移植を中心に、臍帯血、HLA半合致(ハプロ)移植技術の向上を目指し、今に至ります。様々な移植ソースや移植方法を経験してきたことを活かし、それぞれの移植法の特徴をより明らかにして今後の移植医療の方向性を決めたいと考え、現在の研究は臨床研究主体です。昔とった杵柄で、分院内科総合診療科のチェアマンも務めています。
■日本内科学会内科認定医・指導医
■日本血液学会血液専門医・指導医・評議員
■日本造血細胞移植学会移植認定医、評議員
■米国血液学会会員、日本感染症学会会員、日本輸血細胞治療学会会員、など
(2) 研究分野
■成人T細胞白血病(ATL):細胞学、接着分子と臓器特異性の解析、高カルシウム血症のメカニズム、及び、ATLに対する同種造血幹細胞移植(臍帯血移植、HLA半合致移植)
■自施設データを中心とした臍帯血移植における移植後免疫反応、特にpre-engraftment immune reaction:PIR)の病態解析(胸水貯留の意義、重症度分類の試み、GVL効果の検証)、急性・慢性GVHDの解析
■全身放射線非照射前処置での各種同種造血幹細胞移植(臍帯血移植、HLA半合致移植など)の成績向上、全国移植データを用いた各種移植ソースのGVHDやGVL効果の検証
(3) 今後の抱負・アピール
今まで、初診から移植を含めた集学的治療、さらに研究まで自ら関わってきました。現在、当科では、臍帯血移植その他の同種移植術だけでなく、新規治療から臨床経験に基づいた治療に取り組みつつ、その検証を自ら行おうとする若手医師がどんどん育っています。今後は、自分のライフワークであるATLに関する治療成績改善にさらに取り組むとともに、データベースの構築や改善などを通じ、医療の発展に寄与できる医療チームの構築を、あまり出しゃばらずに果たしていきたいと思っています。
(4) 論文・発表
以下、和氣が著者もしくは筆頭発表者となっている代表的な論文です。一部学会発表を含みます。
発表・論文
1: Taya Y, Mitsuki T, Kaji D, Ishiwata K, Wake A. [Successful treatment of acute promyelocytic leukemia complicated by liver cirrhosis with all-trans retinoic acid and reduced-dose anthracycline chemotherapy]. Rinsho Ketsueki. 2018;59(12):2561-2566.
2: Nagafuji K, Miyamoto T, Eto T, Ogawa R, Okumura H, Takase K, Kawano N, Miyazaki Y, Fujisaki T, Wake A, Ohno Y, Kurokawa T, Kamimura T, Takamatsu Y, Yokota S, Akashi K. Prospective evaluation of Minimal Residual Disease (MRD) monitoring to Predict Prognosis of Adult Patients with Ph-negative ALL. Eur J Haematol. 2019 May 27.
3: Kato K, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, Takatsuka Y, Fukuda T, Uchida N, Eto T, Nakashima Y, Kondo T, Taguchi J, Miyamoto T, Nakamae H, Ichinohe T, Kato K, Suzuki R, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019 Feb;37(1):54-61.
4: Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, Yamazaki E, Usuki K, Akazawa K, Kanda J, Minauchi K, Yamamoto G, Tanimoto S, Kamoshita M, Yokoyama Y, Miyaoka E, Ota S, Kako S, Izutsu K, Kanda Y. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study). Hematol Oncol. 2018 Feb;36(1):202-209.
5: 和氣 敦、梶 大介、田矢祐規、成田 円、湯淺光博、景山康生、西田 彩、松野直史、荒岡秀樹、高木伸介、山本久史、石綿一哉、山本 豪、森 有紀、内田直之、伊豆津宏二、牧野茂義、谷口修一. フルダラビン・メルファラン±静注ブスルファンを用いた放射線非照射前処置法による同種移植成績 ー虎の門病院分院の経験ー OS35-2 39th JSHCT 2018
6: Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 2017 Sep;52(9):1261-1267.
7: Fujiwara H, Fuji S, Wake A, Kato K, Takatsuka Y, Fukuda T, Taguchi J, Uchida N, Miyamoto T, Hidaka M, Miyazaki Y, Tomoyose T, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. Bone Marrow Transplant. 2017 Mar;52(3):484-488.
8: Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 2017 Mar;52(3):423-430.
9: Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Takahashi S, Ono Y, Onishi Y, Kanamori H, Aotsuka N, Ozawa Y, Ogawa H, Sakura T, Ohashi K, Ichinohe T, Kato K, Atsuta Y, Teshima T, Murata M. Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. Leukemia. 2017 Mar;31(3):663-668.
10: Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Oct;22(10):1844-1850.
11: Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, Hidaka M, Moriuchi Y, Miyamoto T, Uike N, Taguchi J, Eto T, Tomoyose T, Kondo T, Yamanoha A, Ichinohe T, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016 Feb;51(2):205-11.
12: Yamamoto H, Uchida N, Uchida Y, Nishida A, Ota H, Kageyama K, Nasu I, Wada S, Kaji D, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Matsuno N, Yamamoto G, Masuoka K, Izutsu K, Wake A, Yoneyama A, Makino S, Ito T, Hayashi M, Taniguchi S. Oral beclomethasone dipropionate as an initial treatment for stages 1-2 gastrointestinal tract acute graft-versus-host disease following unrelated cord blood transplantation. Ann Hematol. 2015 Dec;94(12):2073-5.
13: Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, Ikebe T, Nakano N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone Marrow Transplant. 2015 Apr;50(4):607-9.
14: Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Nakamae H, Oku E, Murata M, Eto T, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A. Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant. 2014 Dec;20(12):1968-74.
15: Wake A, Kai S, Okada M, Kato K, Uchida N, Kobayashi N, Aotsuka N, Ishikawa J, Takahashi S, Eto T, Taniguchi S, Atsuta Y, Kato S. Comparison of outcomes after double or single-unit cord blood transplantation in patients with hematological malignancies using TBI-containing myeloablative conditioning regimen, a retrospective matched control study on behalf of C-SHOT0507 and JSHCT registry data in Japan. Blood 2014 124:2548
16: Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1634-40.
17: Takagi S, Araoka H, Uchida N, Uchida Y, Kaji D, Ota H, Nishida A, Ishiwata K, Tsuji M, Yamamoto H, Ito T, Matsuno N, Yamamoto G, Asano-Mori Y, Hayashi M, Izutsu K, Masuoka K, Wake A, Makino S, Yoneyama A, Taniguchi S. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. Int J Hematol. 2014;99(5):652-8.
18: Kai S, Wake A, Okada M, Kurata M, Atsuta Y, Ishikawa J, Nakamae H, Aotsuka N, Kasai M, Misawa M, Taniguchi S, Kato S. Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan. Biol Blood Marrow Transplant. 2013 May;19(5):812-9.
19: Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T, Imamura M, Wake A, Miura K, Hino M, Ishikawa T, Kim JS, Maeda Y, Lee JJ, Kang HJ, Lee HS, Lee JH, Izutsu K, Fukuda T, Kim CW, Yoshino T, Ohshima K, Nakamura S, Nagafuji K, Suzumiya J, Harada M, Kim CS. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia. 2013 Jun;27(6):1394-7.
20: Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M, Ito T, Inoue M, Nagatoshi Y, Takami A, Uike N, Sakamaki H, Yabe H, Morishima Y, Suzuki R, Atsuta Y, Fukuda T. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol. 2012 Dec;96(6):773-80.
21: Matsuno N, Yamamoto H, Watanabe N, Uchida N, Ota H, Nishida A, Ikebe T, Ishiwata K, Nakano N, Tsuji M, Asano-Mori Y, Izutsu K, Masuoka K, Wake A, Yoneyama A, Nakauchi H, Taniguchi S. Rapid T-cell chimerism switch and memory T-cell expansion are associated with pre-engraftment immune reaction early after cord blood transplantation. Br J Haematol. 2013 Jan;160(2):255-8.
22: Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, Ogawa H, Ohashi K, Ohno Y, Aotsuka N, Onishi Y, Kato K, Nagamura-Inoue T, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(2):247-54.
23: Wake A, Uchida N, Yamamoto H, Matsuno N, Nishida A, Shimazu H, Ikebe T, Ota H, Tainosho S, Ishiwata K, Nakano N, Tsuji M, Asano-Mori Y, Izutsu K, Yoneyama A, Makino S, Taniguchi S. Mild pre-engraftment immune reactions may be associated with better survival and GVL effects with less TRM after cord blood transplantation for haematological malignancies. EBMT 2011.
24. Nishida A, Miyamoto A, Yamamaoto H, Uchida N, Izutsu K, Wake A, Ohta Y, Fujii T, Araoka H, Taniguchi S, Kishi K. Possible association of trisomy 8 with secondary pulmonary alveolar proteinosis in myelodysplastic syndrome. Am J Respir Crit Care Med. 2011 Jul 15;184(2):279-80.
25: Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, Yamamoto H, Kato D, Matsuno N, Masuoka K, Araoka H, Asano-Mori Y, Izutsu K, Makino S, Yoneyama A, Taniguchi S. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation. 2011 Aug 15;92(3):366-71.
26: Yamamoto H, Kato D, Uchida N, Ishiwata K, Araoka H, Takagi S, Nakano N, Tsuji M, Asano-Mori Y, Matsuno N, Masuoka K, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood. 2011 Mar 17;117(11):3240-2.
27: Wake A, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Waki F, Takahashi S, Takaue Y, Taniguchi S. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant. 2011 Jun;17(6):841-51.
28: Masuoka K, Uchida N, Ishiwata K, Takagi S, Tsuji M, Yamamoto H, Seo S, Matsuno N, Wake A, Makino S, Yoneyama A, Taniguchi S. What is the upper age limit for performing allo-SCT? Cord blood transplantation for an 82-year-old patient with AML. Bone Marrow Transplant. 2011 Apr;46(4):619-20.
29: Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010 Jul 29;116(4):649-52.
30: Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, Ozawa H, Wake A, Taniguchi S, Shultz LD, Ohara O, Ishikawa F. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010 Feb 3;2(17):17ra9.
31: Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010 Mar;28(3):275-80.
32: Nishida A, Yamamoto H, Ohta Y, Karasawa M, Kato D, Uchida N, Wake A, Taniguchi S. T-cell post-transplant lymphoproliferative disorder in a patient with chronic idiopathic myelofibrosis following allogeneic PBSC transplantation. Bone Marrow Transplant. 2010 Aug;45(8):1372-4.
33: Yamamoto H, Uchida N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Kato D, Matsuhashi Y, Seo S, Matsuno N, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Possible graft-versus-host disease involving the central nervous system soon after cord blood transplantation. Am J Hematol. 2009
Nov;84(11):764-6.34: Takagi S, Masuoka K, Uchida N, Ishiwata K, Araoka H, Tsuji M, Yamamoto H, Kato D, Matsuhashi Y, Kusumi E, Ota Y, Seo S, Matsumura T, Matsuno N, Wake A, Miyakoshi S, Makino S, Ohashi K, Yoneyama A, Taniguchi S. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol. 2009 Nov;147(4):543-53.
35: Wake A, Uchida N, Ishiwata K, Araoka H, Tsuji M, Nakano N, Yamamoto H, Takagi S, Kato D, Matsuno N, Seo S, Asano-Mori Y, Masuoka K, Makino S, Yoneyama A, Taniguchi S. Clinical Characteristics and GVL Effect of Chronic Graft-Versus-Host disease Following Reduced-Intensity Umbilical Cord Blood Transplantation (RICBT). Blood 2009 114:1162
36: Matsuno N, Wake A, Uchida N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Yamamoto H, Kato D, Matsuhashi Y, Seo S, Masuoka K, Miyakoshi S, Makino S, Yoneyama A, Kanda Y, Taniguchi S. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood. 2009 Aug 20;114(8):1689-95.
37: Kim SW, Matsuo K, Fukuda T, Hara M, Matsue K, Taniguchi S, Eto T, Tanimoto M, Wake A, Hatanaka K, Nakao S, Ishida Y, Harada M, Utsunomiya A, Imamura M, Kanda Y, Sunami K, Kawano F, Takaue Y, Teshima T. Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies. Int J Hematol. 2008 Oct;88(3):324-330.
38: Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, Matsumura T, Seo S, Matsuno N, Masuoka K, Kusumi E, Yuji K, Miyakoshi S, Matsuzaki M, Yoneyama A, Taniguchi S. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant. 2008 May;14(5):583-90.
39: Miyakoshi S, Kami M, Tanimoto T, Yamaguchi T, Narimatsu H, Kusumi E, Matsumura T, Takagi S, Kato D, Kishi Y, Murashige N, Yuji K, Uchida N, Masuoka K, Wake A, Taniguchi S. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Transplantation. 2007 Aug 15;84(3):316-22.
40: Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol. 2005 Aug;130(4):575-87.
41: Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S, Kato D, Myojo T, Kusumi E, Masuoka K, Miyakoshi S, Morinaga S, Saji H, Ichinohe T, Taniguchi S. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant. 2005 Sep;36(6):555-6.
42: Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T, Kusumi E, Hara S, Matsumura T, Yuji K, Masuoka K, Wake A, Morinaga S, Kanemaru M, Hayashi T, Tanaka Y, Taniguchi S; Tokyo Stem Cell Transplant Consortium. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005 Jul 15;80(1):34-40.
43: Wake A, Shirakawa K, Kamio M, Yamasaki Y, Sawada H, Izumi Y. Analyses of the allogeneic stem cell transplantation outcome based on the new risk classification. Int J Hematol. 2004 Jan;45(1):48-56.
44: Yamasaki S, Ohno Y, Taniguchi S, Yoshida T, Hayashi S, Ogawa H, Shimazaki C, Takahashi S, Kasai M, Wake A, Nishimura M, Tokunaga K, Gondo H, Takaue Y, Harada M, Mineishi S; Japanese group for blood and marrow transplantation. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies. Bone Marrow Transplant. 2004 Feb;33(3):279-89.
45: Sawada H, Morimoto H, Wake A, Yamasaki Y, Izumi Y. Therapy-related acute myeloid leukemia with t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)(q22;q21). Int J Hematol. 1999 Jun;69(4):270-1.
46: Sawada H, Serino Y, Wake A, Yamasaki Y, Izumi Y. Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside. Leuk Res. 1998 Sep;22(9):853-7.
47: Tanaka Y, Mine S, Figdor CG, Wake A, Hirano H, Tsukada J, Aso M, Fujii K, Saito K, van Kooyk Y, Eto S. Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells. Blood. 1998 May 15;91(10):3909-19.
48: Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, Oda S, Morimoto I, Uno H, Kikuchi H, Izumi Y, Eto S. Distinct phenotype of leukemic T cells with various tissue tropisms. J Immunol. 1997 Apr 15;158(8):3822-9.
49: Nakatsuka K, Tanaka Y, Hubscher S, Abe M, Wake A, Saito K, Morimoto I, Eto S. Rheumatoid synovial fibroblasts are stimulated by the cellular adhesion to T cells through lymphocyte function associated antigen-1/intercellular adhesion molecule-1. J Rheumatol. 1997 Mar;24(3):458-64.
50: Tanaka Y, Kimata K, Wake A, Mine S, Morimoto I, Yamakawa N, Habuchi H, Ashikari S, Yamamoto H, Sakurai K, Yoshida K, Suzuki S, Eto S. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J Exp Med. 1996 Nov 1;184(5):1987-97.
51: Wake A, Tanaka Y, Nakatsuka K, Misago M, Oda S, Morimoto I, Eto S. Calcium-dependent homotypic adhesion through leukocyte function-associated antigen-1/intracellular adhesion molecule-1 induces interleukin-1 and parathyroid hormone-related protein production on adult T-cell leukemia cells in vitro. Blood. 1995 Sep 15;86(6):2257-67.
52: Takasawa A, Wake A, Haratake J, Fujii K, Okada Y, Oda S,Hashimoto H, Morimoto I, Eto S. Autopsy findings of Addison's disease caused by systemic cytomegalovirus infection in a patient with acquired immunodeficiency syndrome. Intern Med. 1995 Jun;34(6):533-6.
53: Mori N, Wake A, Ohsumi K, Murakami S, Shirakawa F, Morimoto I, Oda S, Eto S. Enhancing effect of interleukin-2 on production of parathyroid hormone-related protein by adult T-cell leukemia cells. Jpn J Cancer Res. 1993 Apr;84(4):425-30.
54: Wake A, Kakinuma A, Mori N, Nagata K, Tsukada J, Nakata K, Misago M, Oda S, Morimoto I, Eto S. Angiotropic lymphoma of paranasal sinuses with initial symptoms of oculomotor nerve palsy. Intern Med. 1993 Mar;32(3):237-42.